Yuhan USA team attended NEBS 2024 32nd Annual Conference

Share This Post

Yuhan USA team attended NEBS 2024 32nd Annual Conference on May 18th at the Harvad Medical School.

Yuhan is a proud sponsor of NEBS and it’s always great to connect with such a talented group of scientists.

Special congratulations to Dr. Won-Seok Lee for receiving NEBS-Yuhan award! His work on “Cells with intranuclear Huntingtin aggregates have long (>150) somatic CAG-repeat expansions and associated transcriptional pathology” was indeed impressive.

We look forward to reconnecting at the next event!

New England Bioscience Society, Inc. (NEBS) is a non-profit organization of Korean scientists in the fields of life sciences and biotechnology in New England and Pennsylvania areas. Since its foundation in 1984, NEBS has been dedicated to promoting scientific and social communications and networking among the members.

More To Explore

RYBREVANT® plus LAZCLUZE™ by Johnson & Johnson got approved by the U.S. FDA as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. LAZCLUZE™ is anti-cancer drug developed by Yuhan Corporation licensed out to Janssen Biotech in 2018.  

Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) for the first-line treatment of adult patients

Yuhan August 20, 2024